Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Gross Profit
Ocular Therapeutix Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Gross Profit
$54.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
102%
|
CAGR 10-Years
121%
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Ocular Therapeutix Inc's Gross Profit?
Gross Profit
54.4m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Gross Profit amounts to 54.4m USD.
What is Ocular Therapeutix Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
121%
Over the last year, the Gross Profit growth was 15%. The average annual Gross Profit growth rates for Ocular Therapeutix Inc have been 40% over the past three years , 102% over the past five years , and 121% over the past ten years .